Action TAK TAKEDA PHARMACEUTICAL COMPANY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Takeda Pharmaceutical Company Limited Nyse

Actions

TAK

US8740602052

Marché Fermé - Nyse
Autres places de cotation
 22:00:02 25/06/2024 		Varia. 5j. Varia. 1 janv.
12,98 USD +0,78% Graphique intraday de Takeda Pharmaceutical Company Limited +2,45% -9,04%
25/06 Les CDC américains alertent les prestataires de soins de santé sur l'augmentation du nombre de cas de dengue RE
25/06 Un médicament anticancéreux de Takeda reçoit l'approbation de la Commission européenne MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Takeda Announces New Assignments of Directors
US CDC alerts healthcare providers of increase in dengue cases
Takeda's Cancer Drug Gets European Commission Approval
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
Borsa di Italia: Le streghe terrorizzano l'AI
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4502
  4. Action TAK
  5. Actualités Takeda Pharmaceutical Company Limited
  6. Autres langues